The researchers conducted a two-institution phase II trial of everolimus and letrozole in women with recurrent EC. Everolimus plus letrozole results in a high CBR and RR in patients with recurrent EC. Further development of this combination in recurrent endometrioid EC is under way.

READ FULL ARTICLE Curated publisher From Mdlinx